{
  "_notice": {
    "type": "free_key_offer",
    "message": "Free and anonymous access is staying. If this endpoint is in your pipeline, a free key adds advance notice before any schema change or deprecation. POST /v1/keys {\"email\": \"you@firm.com\"} — nothing else required. Something broken or missing? hello@clearmarket.fyi reaches a human.",
    "docs": "https://clearmarket.fyi/for-data/",
    "policy": "This field is additive and its shape will not change."
  },
  "event_id": "CM-EVT-QSB3J43MQ3",
  "slug": "kxfdaapprovaldatecmps-360",
  "question": "Will the FDA approve Compass Pathways' COMP360 psilocybin? (multi-deadline series, 2027-2028)",
  "category": "technology",
  "event_type": "BINARY",
  "ladder_distribution": null,
  "tags": [
    "technology",
    "psilocybin-therapy",
    "fda-approval",
    "mental-health-treatment",
    "biotech-regulation",
    "compass-pathways"
  ],
  "catalyst_types": [],
  "catalyst_dates": [],
  "editorial_notes": "These markets track FDA approval timing for Compass Pathways' COMP360 psilocybin therapy for treatment-resistant depression. Kalshi structures the event across multiple discrete strike thresholds: January 2027, March 2027, July 2027, October 2027, and 2028. Each threshold is a separate binary, letting traders express approval timing with granularity across a multi-year horizon. Resolution follows Kalshi staff determination, sourced from FDA press announcements confirming approval status.",
  "venues_covered": [
    "kalshi"
  ],
  "primary_market_id": "CM-MKT-BC9G5BVTG4",
  "current_primary_mark": {
    "last_price": 0.78,
    "implied_probability": 0.78
  },
  "created_at": "2026-07-06T00:30:45.836226+00:00",
  "updated_at": "2026-07-06T00:30:45.836226+00:00",
  "markets": [
    {
      "market_id": "CM-MKT-JFVG7M3QN0",
      "event_id": "CM-EVT-QSB3J43MQ3",
      "platform": "kalshi",
      "platform_market_id": "KXFDAAPPROVALDATECMPS-360-27JAN01",
      "question": "Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Jan 1, 2027?",
      "description": "Before Jan 1, 2027",
      "contract_type": "binary",
      "settlement_currency": "USD",
      "underlying_reference": "Before Jan 1, 2027: FDA press announcements will confirm approval status of the referenced therapeutic candidate before July 8, 2027, with Kalshi staff determination on resolution.",
      "close_at": "2027-01-01T04:59:00Z",
      "resolve_at": "2027-01-08T15:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.",
        "arbitration_model": "kalshi_staff",
        "proposer": "platform_staff",
        "source": "Food and Drug Administration",
        "source_status": "platform_named",
        "source_citation": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
        "sources": [
          {
            "name": "Food and Drug Administration",
            "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
            "provenance": "platform_api"
          },
          {
            "name": "FDA",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": "Food and Drug Administration",
        "source_mechanism": "single_authority",
        "source_type": null,
        "source_quality": "authoritative",
        "source_commitment": "named",
        "source_commitment_subtype": "named",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "A",
        "score": 100,
        "caps": [],
        "applied_factors": 6
      },
      "last_price": 0.35,
      "implied_probability": 0.35,
      "volume_24h_usd": 0,
      "volume_total_usd": 642.194,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": "CMX-C31D5A1FE6",
      "also_on": null,
      "tags": [
        "comp360",
        "compass pathways",
        "compass pathways comp360",
        "fda approval",
        "psilocybin",
        "trd",
        "treatment-resistant depression"
      ],
      "eligibility_screens": [
        {
          "regime": "ciro-26-0076",
          "screen_version": "v1",
          "status": "not_eligible",
          "reasons": [
            "category_not_permitted"
          ],
          "bucket": null,
          "screened_at": "2026-06-12"
        }
      ]
    },
    {
      "market_id": "CM-MKT-FW505XSFL3",
      "event_id": "CM-EVT-QSB3J43MQ3",
      "platform": "kalshi",
      "platform_market_id": "KXFDAAPPROVALDATECMPS-360-27MAR01",
      "question": "Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Mar 1, 2027?",
      "description": "Before Mar 1, 2027",
      "contract_type": "binary",
      "settlement_currency": "USD",
      "underlying_reference": "Before Mar 1, 2027: FDA press announcements will confirm approval status of the referenced therapeutic candidate before July 8, 2027, with Kalshi staff determination on resolution.",
      "close_at": "2027-03-01T04:59:00Z",
      "resolve_at": "2027-03-08T15:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.",
        "arbitration_model": "kalshi_staff",
        "proposer": "platform_staff",
        "source": "Food and Drug Administration",
        "source_status": "platform_named",
        "source_citation": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
        "sources": [
          {
            "name": "Food and Drug Administration",
            "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
            "provenance": "platform_api"
          },
          {
            "name": "FDA",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": "Food and Drug Administration",
        "source_mechanism": "single_authority",
        "source_type": null,
        "source_quality": "authoritative",
        "source_commitment": "named",
        "source_commitment_subtype": "named",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "A",
        "score": 100,
        "caps": [],
        "applied_factors": 6
      },
      "last_price": 0.59,
      "implied_probability": 0.59,
      "volume_24h_usd": 0,
      "volume_total_usd": 656.3219,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": "CMX-2214F8F0BF",
      "also_on": null,
      "tags": [
        "comp360",
        "compass pathways",
        "compass pathways comp360",
        "fda approval",
        "psilocybin",
        "trd",
        "treatment-resistant depression"
      ],
      "eligibility_screens": [
        {
          "regime": "ciro-26-0076",
          "screen_version": "v1",
          "status": "not_eligible",
          "reasons": [
            "category_not_permitted"
          ],
          "bucket": null,
          "screened_at": "2026-06-12"
        }
      ]
    },
    {
      "market_id": "CM-MKT-BC9G5BVTG4",
      "event_id": "CM-EVT-QSB3J43MQ3",
      "platform": "kalshi",
      "platform_market_id": "KXFDAAPPROVALDATECMPS-360-27JUL01",
      "question": "When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?",
      "description": "Before July 2027",
      "contract_type": "binary",
      "settlement_currency": "USD",
      "underlying_reference": "Before July 2027: FDA press announcements will confirm approval status of the referenced therapeutic candidate before July 8, 2027, with Kalshi staff determination on resolution.",
      "close_at": "2027-07-01T03:59:00Z",
      "resolve_at": "2027-07-08T14:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.",
        "arbitration_model": "kalshi_staff",
        "proposer": "platform_staff",
        "source": "Food and Drug Administration",
        "source_status": "platform_named",
        "source_citation": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
        "sources": [
          {
            "name": "Food and Drug Administration",
            "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
            "provenance": "platform_api"
          },
          {
            "name": "FDA",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": "Food and Drug Administration",
        "source_mechanism": "single_authority",
        "source_type": null,
        "source_quality": "authoritative",
        "source_commitment": "named",
        "source_commitment_subtype": "named",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "A",
        "score": 100,
        "caps": [],
        "applied_factors": 6
      },
      "last_price": 0.78,
      "implied_probability": 0.78,
      "volume_24h_usd": 0,
      "volume_total_usd": 6207.060600000001,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": null,
      "also_on": null,
      "tags": [
        "comp360",
        "compass pathways",
        "compass pathways comp360",
        "fda approval",
        "psilocybin",
        "trd",
        "treatment-resistant depression"
      ],
      "eligibility_screens": [
        {
          "regime": "ciro-26-0076",
          "screen_version": "v1",
          "status": "not_eligible",
          "reasons": [
            "category_not_permitted"
          ],
          "bucket": null,
          "screened_at": "2026-06-12"
        }
      ]
    },
    {
      "market_id": "CM-MKT-Q9MPL2HF98",
      "event_id": "CM-EVT-QSB3J43MQ3",
      "platform": "kalshi",
      "platform_market_id": "KXFDAAPPROVALDATECMPS-360-27OCT01",
      "question": "When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?",
      "description": "Before October 2027",
      "contract_type": "binary",
      "settlement_currency": "USD",
      "underlying_reference": "Before October 2027: FDA press announcements will confirm approval status of the referenced therapeutic candidate before July 8, 2027, with Kalshi staff determination on resolution.",
      "close_at": "2027-10-01T03:59:00Z",
      "resolve_at": "2027-10-08T14:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.",
        "arbitration_model": "kalshi_staff",
        "proposer": "platform_staff",
        "source": "Food and Drug Administration",
        "source_status": "platform_named",
        "source_citation": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
        "sources": [
          {
            "name": "Food and Drug Administration",
            "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
            "provenance": "platform_api"
          },
          {
            "name": "FDA",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": "Food and Drug Administration",
        "source_mechanism": "single_authority",
        "source_type": null,
        "source_quality": "authoritative",
        "source_commitment": "named",
        "source_commitment_subtype": "named",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "A",
        "score": 100,
        "caps": [],
        "applied_factors": 6
      },
      "last_price": 0.79,
      "implied_probability": 0.79,
      "volume_24h_usd": 0,
      "volume_total_usd": 1850.6856,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": null,
      "also_on": null,
      "tags": [
        "comp360",
        "compass pathways",
        "compass pathways comp360",
        "fda approval",
        "psilocybin",
        "trd",
        "treatment-resistant depression"
      ],
      "eligibility_screens": [
        {
          "regime": "ciro-26-0076",
          "screen_version": "v1",
          "status": "not_eligible",
          "reasons": [
            "category_not_permitted"
          ],
          "bucket": null,
          "screened_at": "2026-06-12"
        }
      ]
    },
    {
      "market_id": "CM-MKT-QQ0QYQC6S8",
      "event_id": "CM-EVT-QSB3J43MQ3",
      "platform": "kalshi",
      "platform_market_id": "KXFDAAPPROVALDATECMPS-360-28JAN01",
      "question": "When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression?",
      "description": "Before 2028",
      "contract_type": "binary",
      "settlement_currency": "USD",
      "underlying_reference": "Before 2028: FDA press announcements will confirm approval status of the referenced therapeutic candidate before July 8, 2027, with Kalshi staff determination on resolution.",
      "close_at": "2028-01-01T04:59:00Z",
      "resolve_at": "2028-01-08T15:00:00Z",
      "status": "open",
      "resolution": {
        "rules_raw": "If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.",
        "arbitration_model": "kalshi_staff",
        "proposer": "platform_staff",
        "source": "Food and Drug Administration",
        "source_status": "platform_named",
        "source_citation": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
        "sources": [
          {
            "name": "Food and Drug Administration",
            "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
            "provenance": "platform_api"
          },
          {
            "name": "FDA",
            "url": null,
            "provenance": "clearmarket_editorial"
          }
        ],
        "source_of_record": "Food and Drug Administration",
        "source_mechanism": "single_authority",
        "source_type": null,
        "source_quality": "authoritative",
        "source_commitment": "named",
        "source_commitment_subtype": "named",
        "source_hedge_text": null
      },
      "rcg": {
        "grade": "A",
        "score": 100,
        "caps": [],
        "applied_factors": 6
      },
      "last_price": 0.82,
      "implied_probability": 0.82,
      "volume_24h_usd": 41,
      "volume_total_usd": 644.7742,
      "settlement_style": "occurrence",
      "direction": "occurrence",
      "threshold": null,
      "question_id": null,
      "also_on": null,
      "tags": [
        "comp360",
        "compass pathways",
        "compass pathways comp360",
        "fda approval",
        "psilocybin",
        "trd",
        "treatment-resistant depression"
      ],
      "eligibility_screens": [
        {
          "regime": "ciro-26-0076",
          "screen_version": "v1",
          "status": "not_eligible",
          "reasons": [
            "category_not_permitted"
          ],
          "bucket": null,
          "screened_at": "2026-06-12"
        }
      ]
    }
  ],
  "resolution_log": [],
  "_provenance": {
    "source": "clearmarket.fyi",
    "ref": "CM-EVT-QSB3J43MQ3",
    "terms": "Attribution required. clearmarket.fyi"
  }
}